Ptc Therapeutics (PTCT) Non-Current Assets (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Non-Current Assets of $633.1 million for Q2 2026, up 75.24% year-over-year from $361.3 million in Q2 2025, and up 2.93% quarter-over-quarter from $615.1 million in Q1 2026.
Ptc Therapeutics (PTCT) Non-Current Assets (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Non-Current Assets history runs 15 years deep, the most recent figure standing at $633.1 million for Q2 2026.
- In Q2 2026, Non-Current Assets rose 75.24% year-over-year to $633.1 million; the TTM figure through Jun 2026 stood at $2.5 billion (up 56.77% YoY), while the FY2025 annual figure was $624.8 million, up 84.04% from the prior year.
- Non-Current Assets for Q2 2026 stood at $633.1 million, up from $615.1 million in the prior quarter.
- The five-year high for Non-Current Assets was $1.1 billion in Q2 2022, with the low at $339.0 million in Q1 2025.
- The 5-year median for Non-Current Assets is $634.5 million (2025), against an average of $702.0 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets tumbled 49.86% in 2024, then jumped 84.04% in 2025.
- Ptc Therapeutics' Non-Current Assets stood at $1.0 billion in 2022, then tumbled by 33.08% to $677.1 million in 2023, then sank by 49.86% to $339.5 million in 2024, then soared by 84.04% to $624.8 million in 2025, then grew by 1.33% to $633.1 million in 2026.
- Business Quant data shows PTCT's Non-Current Assets at $633.1 million in Q2 2026, $615.1 million in Q1 2026, and $624.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 633.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 633.12 Mn |
| Mar 31, 2026 | 615.10 Mn |
| Dec 31, 2025 | 624.82 Mn |
| Sep 30, 2025 | 635.90 Mn |
| Jun 30, 2025 | 361.28 Mn |
| Mar 31, 2025 | 338.98 Mn |
| Dec 31, 2024 | 339.49 Mn |
| Sep 30, 2024 | 560.69 Mn |
| Jun 30, 2024 | 558.45 Mn |
| Mar 31, 2024 | 620.89 Mn |
| Dec 31, 2023 | 677.07 Mn |
| Sep 30, 2023 | 719.52 Mn |
| Jun 30, 2023 | 748.43 Mn |
| Mar 31, 2023 | 995.45 Mn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 30, 2022 | 1.06 Bn |
| Jun 30, 2022 | 1.11 Bn |
| Mar 31, 2022 | 1.03 Bn |
| Dec 31, 2021 | 983.69 Mn |
| Sep 30, 2021 | 996.19 Mn |